TBPH
Theravance Biopharma, Inc.
NASDAQ · Healthcare · Biotechnology · KY
$17.08
+0.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 104.3M | 107.5M | 64.4M | 57.4M | 51.3M |
| Cost of Revenue | 11.1M | 5.5M | 37.6M | 40.6M | 63.4M |
| Gross Profit | 93.3M | 101.9M | 26.7M | 16.8M | (12.0M) |
| Operating Expenses | |||||
| R&D Expense | 25.6M | 37.4M | 38.0M | 46.3M | 70.1M |
| SG&A Expense | 51.8M | 73.7M | 69.2M | 70.5M | 67.1M |
| General & Admin Expense | 14.2M | — | 64.9M | 65.4M | 59.1M |
| Selling & Marketing Expense | — | — | 4.3M | 5.1M | 8.0M |
| Other Expenses | 11.2M | 4.1M | (33.5M) | (44.0M) | (57.2M) |
| Total Operating Expenses | 88.6M | 115.2M | 73.7M | 72.8M | 79.9M |
| Cost and Expenses | 99.7M | 120.7M | 111.3M | 113.5M | 143.3M |
| Operating Income (EBIT) | 4.7M | (13.2M) | (46.9M) | (56.0M) | (92.0M) |
| Non-Operating | |||||
| Interest Income | 10.6M | — | 4.9M | 9.1M | 8.5M |
| Interest Expense | 1.2M | 2.5M | 2.5M | 2.4M | 6.4M |
| Net Interest Income | 9.5M | (2.5M) | 2.3M | 6.8M | 2.2M |
| Other Non-Op Income/Expense | 54.3M | 142.5M | 2.3M | 6.8M | (858.0K) |
| Non-Operating Income (excl Interest) | (59.6M) | (145.0M) | (4.9M) | (2.4M) | (12.8M) |
| EBT (Pre-Tax Income) | 58.9M | 129.2M | (44.6M) | (49.3M) | (92.8M) |
| Income Tax Expense | 5.1M | 23.4M | 11.8M | 5.9M | 9.0K |
| Bottom Line | |||||
| Net Income | 53.8M | 105.9M | (56.4M) | (55.2M) | 872.1M |
| Earnings from Cont. Ops | 53.8M | 105.9M | (56.4M) | (55.2M) | (92.8M) |
| Earnings from Discont. Ops | — | — | — | — | 965.0M |
| Bottom Line Net Income | 53.8M | 105.9M | (56.4M) | (55.2M) | (92.8M) |
| Per Share | |||||
| Basic EPS | $1.06 | $2.10 | ($1.15) | ($1.00) | ($1.26) |
| Diluted EPS | $1.01 | $2.06 | ($1.15) | ($1.00) | ($1.26) |
| Revenue Per Share | $2.02 | $2.14 | $1.32 | $1.04 | $0.70 |
| Shares | |||||
| Basic Shares Outstanding | 51.7M | 50.3M | 48.8M | 55.3M | 73.6M |
| Diluted Shares Outstanding | 51.7M | 51.5M | 48.8M | 55.3M | 73.6M |
| Profitability Metrics | |||||
| EBITDA | 68.5M | 137.2M | (38.5M) | (51.6M) | (76.1M) |
| D&A | 4.2M | 5.5M | 3.6M | 2.0M | 3.0M |
| EBIT | 64.3M | 131.7M | (42.1M) | (53.6M) | (79.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026